Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer
Tóm tắt
Despite advances in treatment of patients with metastatic breast cancer (MBC), prognosis remains poor and median survival is 2–3 years. Resistance to antineoplastics mediated by many factors, potentially including overexpression of drug efflux proteins or altered β-tubulin isotype expression limits the effectiveness of MBC chemotherapy. Capecitabine, approved for anthracycline- and taxane-resistant MBC, has produced modest responses, highlighting the need for more effective treatments for MBC resistant to multiple chemotherapeutic agents. Agents with potential to reverse drug resistance have not proven effective. Albumin-bound paclitaxel is a formulation that may enhance delivery to tumor tissues. Conversely, ixabepilone, an epothilone analog, has been reported to have lower susceptibility to at least some mechanisms of tumor resistance and clinical activity in resistant/refractory MBC. The topoisomerase-I inhibitor irinotecan also has low cross-resistance with other antineoplastics, and has shown some activity against refractory MBC. Development of new agents and identification of genetic biomarkers in translational studies promise to improve management of patients with resistant/refractory breast cancer.
Tài liệu tham khảo
Jemal A, Siegel R, Ward E et al (2008) Cancer Statistics, 2008. Available via CA Cancer J Clin. http://caoline.amcancersoc.org/cgi/content/full/CA.2007.0010v1. Accessed 5 Mar 2008
Ries LAG, Melbert D, Krapcho M et al (eds) (2006) SEER Cancer Statistics Review, 1975–2004, National Cancer Institute. http://seer.cancer.gov/csr/1975_2004. Accessed 11 Feb 2008
Bernard-Marty C, Cardoso F, Piccart MJ (2004) Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 9:617–632
Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726
Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743
NCCN (2008) Breast cancer; clinical practice guidelines in oncology - v.2. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed 11 Feb 2008
Hamilton A, Hortobagyi G (2005) Chemotherapy: what progress in the last 5 years? J Clin Oncol 23:1760–1775
Fujiwara Y (1999) Current status of oral anticancer drugs in Japan. J Clin Oncol 17:3362–3365
Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN (2004) Is breast cancer survival improving? Cancer 100:44–52
Bonneterre J, Dieras V, Tubiana-Hulin M et al (2004) Phase II multicentre randomised study of docetaxel plus epirubicin vs. 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 91:1466–1471
Ishikawa T, Shimizu S, Inaba M et al (2004) A multicenter phase II study of docetaxel 60 mg/m2 as first-line chemotherapy in patients with advanced or recurrent breast cancer. Breast Cancer 11:374–379
Vassilomanolakis M, Koumakis G, Barbounis V et al (2005) First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer. Breast 14:136–141
Porkka K, Blomqvist C, Rissanen P, Elomaa I, Pyrhönen S (1994) Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol 12:1639–1647
Gottesman M (2002) Mechanisms of cancer drug resistance. Ann Rev Med 53:615–627
Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD (2003) Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 6:71–84
Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295–1302
Leonard GD, Fojo T, Bates SE (2003) The role of ABC transporters in clinical practice. Oncologist 8:411–424
Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58
Chen YN, Mickley LA, Schwartz AM, Acton EM, Hwang J, Fojo AT (1990) Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 265:10073–10080
Doyle LA, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340–7358
Yang CH, Schneider E, Kuo ML, Volk EL, Rocchi E, Chen YC (2000) BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem Pharmacol 60:831–837
Trock BJ, Leonessa F, Clarke R (1997) Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89:917–931
Leonessa F, Clarke R (2003) ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10:43–73
Kavallaris M (1997) The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance. Anti-Cancer Drugs 8:17–25
Honjo Y, Hrycyna CA, Yan QW et al (2001) Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61:6635–6639
Verrills NM, Kavallaris M (2005) Improving the targeting of tubulin-binding agents: lessons from drug resistance studies. Curr Pharm Des 11:1719–1733
Paradiso A, Mangia A, Chiriatti A et al (2005) Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 16(suppl. 4):iv14–iv19
Kamath K, Wilson L, Cabral F, Jordan MA (2005) ßIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 280:12902–12907
Zhu H, Guo W, Zhang L et al (2005) Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther 4:451–456
Brooks T, Minderman H, O’Loughlin KL et al (2003) Taxane-based reversal agents modulate drug resistance mediated by p-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2:1195–1205
Thomas H, Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10:159–165
Menefee M, Fan C, Edgerly M et al (2005) Tariquidar (XR9576) is a potent and effective p-glycoprotein (pgp) inhibitor that can be administered safely with chemotherapy. J Clin Oncol 23:16S Abstract 3093
Pusztai L, Wagner P, Ibrahim N et al (2005) Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104:682–691
Fumoleau P, Largillier R, Clippe C et al (2004) Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40:536–542
Xeloda tablets [package insert] (2006) Nutley, NJ: Roche Pharmaceuticals
Blum JL, Jones SE, Buzdar AU et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485–493
Blum JL (2001) The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 6:56–64
Blum JL, Dieras V, Lo Russo PM et al (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759–1768
Reichardt P, von Minckwitz G, Thuss-Patience PC et al (2003) Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14:1227–1233
Wist EA, Sommer HH, Østenstad B, Risbert T, Bremnes Y, Mjaaland I (2004) Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 43:186–189
Petit T, Benider A, Yovine A et al (2006) Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer. Anticancer Drugs 17:337–343
Zelek L, Cottu P, Tubiana-Hulin M et al (2002) Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol 20:2551–2558
Perez EA (2004) Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes. Clin Breast Cancer 4:S113–S116
Burch PA, Mailliard JA, Hillman DW et al (2005) Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group trial. Am J Clin Oncol 28:195–200
Seo JH, Oh SC, Choi CW et al (2007) Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer. Cancer Chemother Pharmacol 59:269–274
Blum JL, Savin MA, Edelman G et al (2004) Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel. J Clin Oncol 22:14S Abstract 543
Dieras V, Valero V, Limentani S et al (2005) Multicenter, non-randomized phase II study with RPR109881 in taxane-exposed metastatic breast cancer (MBC) patients (pts): final results. J Clin Oncol 23:16S Abstract 565
Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803
Capecitabine and paclitaxel (albumin-stabilized nanoparticle formulation) in treating women undergoing surgery for stage II or stage III breast cancer. http://clinicaltrials.gov/ct2/show/NCT00397761. Accessed 8 Feb 2008
Chemotherapy, G-CSF, and ABI-007 with or without trastuzumab in treating women with high-risk localized breast cancer. http://clinicaltrials.gov/ct2/show/NCT00407888. Accessed 8 Feb 2008
Paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, and gemcitabine as first-line therapy in treating patients with metastatic breast cancer. http://clinicaltrials.gov/ct2/show/NCT00503906. Accessed 8 Feb 2008
Combination study of a new taxane and capecitabine in patients with metastatic breast cancer. http://clinicaltrials.gov/ct2/show/NCT00327743. Accessed 8 Feb 2008
Study of larotaxel 90 mg/m2 or docetaxel every 3 weeks, alone or with trastuzumab according to Her2/neu status, after combination of anthracycline and cyclophosphamide as preoperative therapy in patients with high risk localized breast cancer. http://clinicaltrials.gov/ct2/show/NCT00485979. Accessed 3 Mar 2008
Study of larotaxel in combination with weekly herceptin® in patients with HER2 positive metastatic breast cancer. http://clinicaltrials.gov/ct2/show/NCT00387907. Accessed 8 Feb 2008
O’Shaughnessy JA, Clark RS, Blum JL et al (2005) Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer 6:143–149
Vukelja S, O’Shaughnessy J, Campos S et al (2005) Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: phase 2 study results. J Clin Oncol 23:16S Abstract 562
Perez EA, Hillman DW, Mailliard JA et al (2004) Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22:2849–2855
Perez EA, Lerzo G, Pivot X et al (2007) Efficacy and safety of ixabepilone (BMS–247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407–3414
Lee FY, Borzilleri R, Fairchild CR et al (2001) BMS–247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429–1437
Bollag DM, McQueney PA, Zhu J et al (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325–2333
Chin YW, Balunas MJ, Chai HB, Kinghorn AD (2006) Drug discovery from natural resources. AAPS J 8:E239–E253
Giannakakou P, Gussio R, Nogales E et al (2000) A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 97:2904–2909
Giannakakou P, Sackett DL, Kang YK et al (1997) Paclitaxel-resistant human ovarian cancer cells have mutant ß-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118–17125
Cortes J, Baselga J (2007) Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 12:271–280
Zhou Y, Zhong Z, Liu F et al (2005) KOS-1584: a rationally designed epothilone D analog with improved potency and pharmacokinetic (PK) properties. Proc Amer Assoc Cancer Res 46: Abstract 2535
Jordan MA, Miller H, Ni L et al (2006) The Pat-21 breast cancer model derived from a patient with primary taxol® resistance recapitulates the phenotype of its origin has altered beta-tubulin expression and is sensitive to ixabepilone. The 97th AACR Annual Meeting, Washington DC, April 1–5, 2006 Abstract LB-280
Thomas E, Tabernero J, Fornier M et al (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25:3399–3406
Valero V, Jones SE, Von Hoff DD et al (1998) A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16:3362–3368
Thomas ES, Gomez HL, Li RK et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210–5217